Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Expected to Achieve 8.6% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size By 2025?
In recent years, the market size for sodium glucose cotransporter 2 (SGLT2) inhibitors has seen substantial growth. The market is expected to expand from $10.17 billion in 2024 to $11.07 billion in 2025, with a compound annual growth rate (CAGR) of 8.8%. This growth during the historical period can be linked to successes in early clinical trials, a rise in regulatory approvals, an increase in the diagnosis of diabetes, and the need for novel diabetes treatments.

How Big Is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size Expected to Grow by 2029?
The market size for sodium glucose cotransporter 2 (SGLT2) inhibitors is predicted to witness significant escalation in the upcoming years, expanding to $15.4 billion by 2029 at a compound annual growth rate of 8.6%. The projected increase in the futuristic period is due to the surge in diabetes cases, swelling rates of obesity, rising consciousness around diabetes control, and broader uses in treating heart and kidney diseases. Key trends during the forecast period comprise the amalgamation of combined treatments, customised medicine strategies, technological advancements, and conventional drug production.

View the full report here:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

Which Key Market Drivers Powering Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Expansion and Growth?
The sodium glucose cotransporter 2 (SGLT2) inhibitor market is predicted to flourish due to the upswing in diabetes occurrences. Diabetes is a collective term for metabolic diseases associated with elevated blood sugar levels, resulting from problems related to either insulin secretion, insulin functioning, or both. The proliferation of diabetes can be connected to elements like urbanization, stress, environmental contaminations, and insufficient availability of healthcare amenities. SGLT2 inhibitors, used for diabetes management, help lower blood sugar levels by obstructing glucose absorption in the kidneys, which then gets expelled through urine. Furthermore, these inhibitors provide cardiovascular and renal advantages, making them an effective tool against diabetes and associated complications. For example, data from the Australian Bureau of Statistics, a government organization in Australia, revealed that in 2022, around 5.3% of Australians, approximating 1.3 million individuals, were diagnosed with diabetes. The rates were almost equivalent for men (5.8%) and women (4.9%). Like wise, the incidence of diabetes is on the rise, noticeably spiking amongst individuals 75 and above, reaching a percentage of 18.7%. Type 2 diabetes is most prevalent, comprising 87.6% of all situations. Factors including overseas birth, residency in disadvantaged regions, and disabilities are linked with elevated diabetes rates. Accordingly, the escalating occurrence of diabetes is stimulating the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Prominent businesses in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating on the creation of dual inhibitor therapeutic treatments, with the aim of bettering patient outcomes and regulating blood sugar levels. These solutions target two distinct sodium-glucose cotransporters (SGLT1 and SGLT2), simultaneously, to increase efficacy in managing ailments, such as heart problems and diabetes. One such example is Lexicon Pharmaceuticals Inc., a biopharmaceutical company based in the US, which in May 2023 got a nod from the Food and Drug Administration (FDA) for their treatment, sotagliflozin, intended for heart failure. This treatment, also being the first of its kind, is a dual inhibitor of sodium-glucose cotransporters 1 and 2, comes in a daily dose tablet, and is formulated to decrease cardiovascular mortality, hospitalisations due to heart failure, and critical heart failure related visits among adults who are prone to heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk inducing factors. It has several benefits, such as decreasing renal glucose and sodium reabsorption, which consequently lead to a decrease in preload and afterload along with a reduction in sympathetic activity.

What Are the Emerging Segments in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented -

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

Who Are the Global Leaders in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.

Which are the Top Profitable Regional Markets for the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.